Regen BioPharma Inc (OTCMKTS:RGBP) Stock Attempts To Bounce Back After Recent Fall

Shares of Regen BioPharma Inc (OTCMKTS:RGBP) bounced back a bit in the previous sessions.

Market Stats     

On Thursday, RGBP stock gained 5.33% to $0.0079 with more than 23.96 million shares, compared to its average volume of 36.57 million shares. The stock moved within a range of $0.0071 – 0.0085 after opening trading at $0.0084.

Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies

Publicly traded biotechnology company, Regen BioPharma Inc (OTCMKTS:RGBP) on March 10, 2022 announced program for acceleration of clinical development of NR2F6 therapies. The firm is aiming to combine altered mRNA technology with Regen’s existing siRNA (small interfering RNA) intellectual property. This will be potentially a vital immune cell inhibitor  and cancer stem cell differentiator.

A single-stranded molecule carrying genetic code, mRNA is in cell’s nucleus to ribosomes. Regen has done an Investigational New Drug Application for its drug termed tCellVax with U.S. FDA. Aimed at utilising siRNA for silencing NR2F6 activity in human immune cells, leading to attacking cancer cells. The firm opines that putting on new intellectual property changing mRNA will deepen drug development process. Dyo Biotechnologies has been given contract for helping Regen with development of the technology.

David Koos, CEO and Chairman of Regen said that the CellVax drug is a significant development in cancer immunotherapy. Koos added that the new mRNA intellectual property for tCellVax can simplify administration to patients. The CEO also said that RNA-based checkpoint inhibitor can l be a first-in-class drug.

The company is looking to draft a fresh patent application on the intellectual property. Regen is in the process of drafting a new patent application pertaining to this intellectual property. Regen BioPharma is focusing on immunology and immunotherapy space.

Key Quote

“I believe our tCellVax drug as it stands today is a potentially major new development in the field of cancer immunotherapy. We believe that by adding our new mRNA intellectual property to tCellVax we can simplify its administration to patients and thus create a much more marketable drug,” says David Koos, CEO and Chairman of Regen. “An RNA-based checkpoint inhibitor will be a first-in-class drug.”

Traders Corner

RGBP stock is trading above the 20-Day and 50-Day Moving averages of $0.0090 and $0.0107 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0202.

Madison Hall

After graduating from the University of Buffalo, Madison gained a real interest in the markets. She tends to be a swing trader and enjoys Pilates and yoga in her downtime.